3 results
Primary objectiveTo compare the progression-free survival (PFS) of subjects treated with either pimasertib or dacarbazine.Secondary objectivesEfficacy- To compare the objective response of subjects treated with either pimasertib or dacarbazine.- To…
To analyze the molecular effects and dose-response relationship of HBOT in patients with moderate-to-severe UC refractory to medical therapy, more specifically to evaluate: - Clinical, endoscopic, histological and ultrasonographic disease activity-…
To study whether ziltivekimab therapy reduces arterial wall inflammation as assessed by imaging, and reduces the systemic inflammatory tone as assessed by circulating monocytes, inflammatory biomarkers and proteomics.